Safety and efficacy of mFOLFOX6+panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naive metastatic colorectal cancer (SAPPHIRE)

被引：0
|
作者：
Nagata, N. [1 ]
Mishima, H. [2 ]
Kurosawa, S. [3 ]
Oba, K. [4 ]
Sakamoto, J. [5 ]
机构：
[1] Kitakyushu Gen Hosp, Surg, Kitakyushu, Fukuoka, Japan
[2] Aichi Med Univ, Clin Oncol, Nagakute, Aichi 48011, Japan
[3] Takeda Pharmaceut Co Ltd, GMA J, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Sch Publ Hlth, Biostat, Tokyo, Japan
[5] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228TiP
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [21] Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC)
    Price, T. J.
    Peeters, M.
    Douillard, J.
    Mitchell, E.
    Cohn, A.
    Strickland, A. H.
    Rivera, F.
    Xu, F.
    Gansert, J.
    Siena, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
    Pietrantonio, Filippo
    Bergamo, Francesca
    Rossini, Daniele
    Ghelardi, Filippo
    De Grandis, Maria Caterina
    Germani, Marco Maria
    Barsotti, Giulia
    Formica, Vincenzo
    Frassineti, Giovanni Luca
    Boscolo, Giorgia
    Cinieri, Saverio
    Di Donato, Samantha
    Antonuzzo, Lorenzo
    Antoniotti, Carlotta
    Ambrosini, Margherita
    Piva, Vittoria Matilde
    Nichetti, Federico
    Fassan, Matteo
    Cremolini, Chiara
    Lonardi, Sara
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [23] Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution
    Sonoda, Hiromichi
    Mekata, Eiji
    Shimizu, Tomoharu
    Endo, Yoshihiro
    Tani, Tohru
    ONCOLOGY LETTERS, 2013, 5 (04) : 1331 - 1334
  • [24] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [25] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC)
    Cavanna, Luigi
    Artioli, Fabrizio
    Codignola, Claudio
    Lazzaro, Antonio
    Rizzi, Anna
    Gamboni, Alessandro
    Rota, Luigina
    Rodino, Carmelina
    Boni, Fabrizio
    Iop, Aldo
    Zaniboni, Alberto
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 371 - 375
  • [26] Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Yamanaka, Kazunori
    Iwasaki, Kouji
    Soeda, Jumpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Muro, Kei
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 158 - 163
  • [27] A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.
    Redlinger, M
    Kramer, A
    Flaherty, K
    Sun, W
    Haller, D
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [28] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [29] First line therapy of Panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC)
    Berlin, J.
    Posey, J.
    Tchekmedyian, S.
    Hu, E.
    Chan, D.
    Malik, I.
    Yang, L.
    MacDonald, M.
    Jerian, S.
    Hecht, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 185 - 185
  • [30] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    Medical Oncology, 2014, 31
12345